Avalo Therapeutics Statistics
Share Statistics
Avalo Therapeutics has 10.46M shares outstanding. The number of shares has increased by 1205.32% in one year.
| Shares Outstanding | 10.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.87% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.40M |
| Failed to Deliver (FTD) Shares | 341 |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 22.92K, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 22.92K |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 0.27 |
Valuation Ratios
The PE ratio is -0.08 and the forward PE ratio is -2.73.
| PE Ratio | -0.08 |
| Forward PE | -2.73 |
| PS Ratio | 1.31 |
| Forward PS | 68 |
| PB Ratio | 0.35 |
| P/FCF Ratio | -0.08 |
| PEG Ratio | n/a |
Enterprise Valuation
Avalo Therapeutics Inc. has an Enterprise Value (EV) of -985.68K.
| EV / Earnings | 0.03 |
| EV / Sales | -0.51 |
| EV / EBITDA | 0.04 |
| EV / EBIT | 0.04 |
| EV / FCF | 0.03 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.
| Current Ratio | 1.82 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -6.86 |
Financial Efficiency
Return on equity (ROE) is -4.32% and return on capital (ROIC) is -299.13%.
| Return on Equity (ROE) | -4.32% |
| Return on Assets (ROA) | -1.5% |
| Return on Capital (ROIC) | -299.13% |
| Revenue Per Employee | 101.26K |
| Profits Per Employee | -1.66M |
| Employee Count | 19 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 14.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 36.84% in the last 52 weeks. The beta is 1.03, so Avalo Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.03 |
| 52-Week Price Change | 36.84% |
| 50-Day Moving Average | 10.09 |
| 200-Day Moving Average | 11.21 |
| Relative Strength Index (RSI) | 27.11 |
| Average Volume (20 Days) | 90.16K |
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 1.92M and earned -31.54M in profits. Earnings per share was -113.58.
| Revenue | 1.92M |
| Gross Profit | 640.00K |
| Operating Income | -23.44M |
| Net Income | -31.54M |
| EBITDA | -27.95M |
| EBIT | -23.44M |
| Earnings Per Share (EPS) | -113.58 |
Balance Sheet
The company has 7.42M in cash and 537.00K in debt, giving a net cash position of 6.88M.
| Cash & Cash Equivalents | 7.42M |
| Total Debt | 537.00K |
| Net Cash | 6.88M |
| Retained Earnings | -335.13M |
| Total Assets | 98.45M |
| Working Capital | 25.47M |
Cash Flow
In the last 12 months, operating cash flow was -30.68M and capital expenditures -158.00K, giving a free cash flow of -30.84M.
| Operating Cash Flow | -30.68M |
| Capital Expenditures | -158.00K |
| Free Cash Flow | -30.84M |
| FCF Per Share | -111.04 |
Margins
Gross margin is 33.26%, with operating and profit margins of -1.22K% and -1.64K%.
| Gross Margin | 33.26% |
| Operating Margin | -1.22K% |
| Pretax Margin | -1.64K% |
| Profit Margin | -1.64K% |
| EBITDA Margin | -1.45K% |
| EBIT Margin | -1.22K% |
| FCF Margin | -1.60K% |
Dividends & Yields
AVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1747.38% |
| FCF Yield | -45.34% |
Analyst Forecast
The average price target for AVTX is $35, which is 438.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 438.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Dec 29, 2023. It was a backward split with a ratio of 1:240.
| Last Split Date | Dec 29, 2023 |
| Split Type | backward |
| Split Ratio | 1:240 |
Scores
| Altman Z-Score | -5.01 |
| Piotroski F-Score | 1 |